Search

Your search keyword '"Boz, Gianni"' showing total 11 results
Start Over Author "Boz, Gianni"
11 results on '"Boz, Gianni"'

1. Open radiofrequency ablation as upfront treatment for locally advanced pancreatic cancer: Requiem from a randomized controlled trial

Author

Frigerio, Isabella, Paiella, Salvatore, Barbi, Emilio, Bianco, Roberto, Boz, Gianni, Butturini, Giovanni, Cantore, Maurizio, Cardarelli, Nadia, Mirko, D'Onofrio, Fiorentini, Gianmaria, Giardino, Alessandro, Lionetto, Gabriella, Malleo, Giuseppe, Mambrini, Andrea, Milella, Michele, Passardi, Alessandro, Regi, Paolo, Salvia, Roberto, Scopelliti, Filippo, Viviani, Elena, Bassi, Claudio, and Girelli, Roberto

Published
2021
Full Text
View/download PDF

4. Simultaneous radiochemotherapy in the treatment of inoperable, locally advanced head and neck cancers: a single-institution study

Author

Franchin, Giovanni, Gobitti, Carlo, Minatel, Emilio, Barzan, Luigi, De Paoli, Antonino, Boz, Gianni, Mascarin, Maurizio, Lamon, Stefano, and Trovo, Mauro G.

Subjects
Head and neck cancer -- Care and treatment, Combined modality therapy -- Evaluation, Health
Abstract

Background. Patients with advanced, inoperable head and neck cancers have cure rates of approximately 10-15%. In these patients, concomitant chemoradiotherapy seems to improve local control and survival. 5-Fluorouracil (5-FU) administered by continuous infusion and cisplatin plus concomitant conventional radiation therapy may be promising in treating advanced, inoperable head and neck cancers. Methods. Forty-five evaluable patients with primary nonmetastatic, inoperable head and neck cancers were treated. From January 1987 to April 1988, the patients were treated with cisplatin plus radiation therapy (Group 1) and from May 1988 to November 1990, they were treated with the same combination plus 5-FU, given in continuous infusion (Group 2). Clinical and pathologic responses were assessed after radiation therapy was completed. Patients who relapsed underwent salvage surgery, if possible. The disease free and overall survival rates of the patients were evaluated. Results. The overall response rate (complete and partial response) was 93%, 60% of which comprised complete remissions. Despite the high response rates obtained in the two groups, the time to progression for complete responses and the median survival time were unsatisfactory (13 [Group 1] and 10 months [Group 2] and 17 [Group 1] and 16 months [Group 2], respectively). The toxicity rate from the two treatments was not relevant. A Grade II mucositis, according to the World Health Organization, was found in 25 patients, and the treatment was interrupted for 7-10 days in 5. Conclusions. In this study, despite an improvement in the number of complete responses, the chemotherapeutic regimen with or without 5-FU did not prolong the overall patient survival significantly. Cancer 1995;75: 1025-9.

Published
1995

5. Inter-observer variability of clinical target volume delineation in radiotherapy treatment of pancreatic cancer: a multi-institutional contouring experience

Author

Caravatta, Luciana, primary, Macchia, Gabriella, additional, Mattiucci, Gian Carlo, additional, Sainato, Aldo, additional, Cernusco, Nunzia LV, additional, Mantello, Giovanna, additional, Di Tommaso, Monica, additional, Trignani, Marianna, additional, De Paoli, Antonino, additional, Boz, Gianni, additional, Friso, Maria L, additional, Fusco, Vincenzo, additional, Di Nicola, Marta, additional, Morganti, Alessio G, additional, and Genovesi, Domenico, additional

Published
2014
Full Text
View/download PDF

6. Offlabel nab-paclitaxel: Gemcitabine chemotherapy in advanced pancreatic cancer—A monoinstitutional experience.

Author

Lo Re, Giovanni, primary, Santeufemia, Davide Adriano, additional, Ius, Antonino, additional, Del Conte, Alessandro, additional, Foltran, Luisa, additional, Fadda, Giovanni Maria, additional, Basso, Stefano Maria, additional, Marus, Wally, additional, Chiara, Giordano Bruno, additional, Stuto, Angelo, additional, Tosolini, Giancarlo, additional, Sulfaro, Sandro, additional, Spaziante, Roberto, additional, Nicolosi, Gianluigi, additional, Boz, Gianni, additional, Mancinelli, Paolo, additional, Tumolo, Salvatore, additional, Bidoli, Ettore, additional, and Cozzi, Cinzia, additional

Published
2014
Full Text
View/download PDF

11. Open radiofrequency ablation as upfront treatment for locally advanced pancreatic cancer: Requiem from a randomized controlled trial

Author

Emilio Barbi, Alessandro Passardi, Claudio Bassi, Alessandro Giardino, D'Onofrio Mirko, Roberto Girelli, Roberto Bianco, Gianni Boz, Giuseppe Malleo, Michele Milella, Andrea Mambrini, P. Regi, Isabella Frigerio, Elena Viviani, G. Fiorentini, Filippo Scopelliti, Maurizio Cantore, Roberto Salvia, Salvatore Paiella, Nadia Cardarelli, Gabriella Lionetto, Giovanni Butturini, Frigerio, Isabella, Paiella, Salvatore, Barbi, Emilio, Bianco, Roberto, Boz, Gianni, Butturini, Giovanni, Cantore, Maurizio, Cardarelli, Nadia, Mirko, D'Onofrio, Fiorentini, Gianmaria, Giardino, Alessandro, Lionetto, Gabriella, Malleo, Giuseppe, Mambrini, Andrea, Milella, Michele, Passardi, Alessandro, Regi, Paolo, Salvia, Roberto, Scopelliti, Filippo, Viviani, Elena, Bassi, Claudio, and Girelli, Roberto

Subjects
RFA, medicine.medical_specialty, Ablative therapy, Radiofrequency ablation, Endocrinology, Diabetes and Metabolism, Context (language use), law.invention, Advanced PDAC, 03 medical and health sciences, 0302 clinical medicine, Randomized controlled trial, law, Statistical significance, Pancreatic cancer, medicine, Humans, Pancrea, In patient, Pancreas, Radiofrequency Ablation, Hepatology, business.industry, Liver Neoplasms, Gastroenterology, Pancreatic Neoplasm, medicine.disease, Progression-Free Survival, Surgery, Locally advanced pancreatic cancer, Pancreatic Neoplasms, Treatment Outcome, Liver Neoplasm, 030220 oncology & carcinogenesis, Catheter Ablation, 030211 gastroenterology & hepatology, business, Chemoradiotherapy, Human
Abstract

Background Local ablation of pancreatic cancer has been suggested as an option to manage locally advanced pancreatic cancer (LAPC) although no robust evidence has been published to date to support its application. The aim of this study is to compare overall survival (OS) and progression-free survival (PFS) in patients receiving both radiofrequency ablation (RFA) and conventional chemoradiotherapy (CHRT) with patients receiving CHRT only. Methods This is a multicentre prospective randomized controlled trial (RCT). Patients with LAPC diagnosed by the Pancreas-Ablation-Team-Verona were randomly assigned to open RFA (Group A) or CHRT (Group B). Survival analyses were performed using the Kaplan-Meier method and compared using the log-rank test. Statistical significance was set at p Results One hundred LAPC patients were enrolled from January 2014 to August 2016. 33% of patients in Group A did not receive the designated procedure because of intraoperative findings of liver (18.7%) or peritoneal metastases (43.8%), or technical contraindications (37.5%). We did not observe any statistically significant survival benefit from RFA compared to CHRT, neither in terms of OS (medians of 14.2 months and 18.1 months, respectively, p = 0.639) nor PFS (medians of 8 months and 6 months respectively, p = 0.570). Mortality was nil and RFA-related morbidity was 15.6%. In 13% of subjects, conversion to surgery occurred (2 after RFA and 11 after CHRT). Conclusions This is the first RCT evaluating the impact of upfront RFA in the multimodal treatment of LAPC. Compared to CHRT, RFA alone did not provide any advantage in terms of OS or PFS. It could be considered as a therapeutic option for LAPC within a multimodal context and after neoadjuvant therapies.

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results